Becton Dickinson (NYSE: BDX) EVP sells 75 shares in 10b5-1 trade

Rhea-AI Filing Summary

Becton, Dickinson and Company executive Michael Feld, EVP, CRO & President of Life Sciences, reported selling 75 shares of BDX common stock on January 26, 2026 at a price of $202.73 per share. Following this sale, he directly beneficially owns 16,431 shares. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan that Feld adopted on February 7, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Feld Michael

(Last) (First) (Middle)

C/O BECTON, DICKINSON AND COMPANY

1 BECTON DRIVE

(Street)

FRANKLIN LAKES NJ 07417

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BECTON DICKINSON & CO [ BDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CRO & Pres. Life Sciences

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/26/2026		S		75	D	$202.73	16,431	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 7, 2025.

	Donna Kalazdy, by power of attorney from Michael Feld	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Becton Dickinson (BDX) report for Michael Feld?

Michael Feld reported selling 75 shares of Becton Dickinson common stock. The sale occurred on January 26, 2026 at a price of $202.73 per share, as disclosed in a Form 4 insider trading report.

How many Becton Dickinson (BDX) shares does Michael Feld own after this sale?

After the reported transaction, Michael Feld beneficially owns 16,431 shares of Becton Dickinson common stock. These shares are listed as held directly in his name in the Form 4 filing.

Was Michael Feld’s Becton Dickinson (BDX) stock sale part of a 10b5-1 plan?

Yes. The Form 4 states the sale was made under a Rule 10b5-1 trading plan. This plan was adopted by Michael Feld on February 7, 2025, providing a pre-arranged framework for selling shares.

What is Michael Feld’s role at Becton Dickinson (BDX) in this Form 4?

Michael Feld is identified as an officer of Becton Dickinson, serving as EVP, Chief Regulatory Officer (CRO) and President, Life Sciences. The Form 4 confirms he is not a director or 10% owner.

What type of security did Michael Feld sell in the Becton Dickinson (BDX) filing?

The transaction involved common stock of Becton Dickinson. Table I of the Form 4 shows a sale of 75 shares of common stock, with no derivative securities transactions reported in Table II.